Loading…
Employees: 1,114
Size Kaken Pharmaceutical (4521.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $854M, the 812th largest of 1,379 Japan companies the cockpit tracks. Shares closed at ¥3,740 on 6 Nov 2026.
Performance Over six months the shares fell 8.3%, against -11.9% for the median peer and +1.8% for the Japan market (cap-weighted) — 9th highest of 20 in its peer set.
Growth Revenue fell 6.9% over the last twelve months (peer median +2.4%); the operating margin is 11.3% (peer median 3.6%).
Valuation It trades at 24.5× forward earnings against a peer median of 19.1× (4th cheapest of 7).
Capital Return on invested capital runs 2.0 points above its cost of capital (5.0% WACC).
Next results Next results expected around 9 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥88.2B | ¥76.9B | ¥94.0B | ¥72.0B | ¥73.0B |
| Revenue growth | — | -18% | +31% | -1% | — |
| Gross profit | ¥51.1B | ¥39.2B | ¥58.3B | ¥38.2B | ¥39.3B |
| EBITDA | ¥13.7B | ¥2.43B | ¥23.6B | ¥12.3B | ¥10.6B |
| Net income | ¥10.3B | ¥2.14B | ¥13.9B | ¥8.03B | ¥5.44B |
| Free cash flow | n/a | -¥14.1B | ¥25.6B | ¥716M | ¥7.27B |
| Capital expenditure | n/a | ¥5.72B | ¥4.66B | ¥2.17B | ¥2.21B |
| Total debt | ¥4.26B | ¥3.94B | ¥3.96B | ¥3.85B | ¥3.85B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4521.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.8% | -9.5% | 5th highest of 21 |
| 6-month return | -8.3% | -11.9% | 9th highest of 20 |
| Distance from 52-week high | -15.9% | -33.9% | 3rd highest of 21 |
| Revenue growth (TTM) | -6.9% | +2.4% | 5th lowest of 19 |
| Operating margin | 11.3% | 3.6% | 7th highest of 19 |
| Forward P/E | 24.5× | 19.1× | 4th cheapest of 7 |
| ROIC minus cost of capital | +2.0 pp | -2.1 pp | 6th highest of 17 |
| EV / EBITDA | 5.9× | 17.8× | 2nd cheapest of 8 |
| Net debt / EBITDA | -3.9× | 1.8× | least indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Kaken Pharmaceutical 4521.T | Japan | $854M | -8% | -7% | 11% | 24.5× | n/a | n/a |
| Hygeia Healthcare 6078.HK | Hong Kong | $861M | -7% | +2% | 14% | 11.0× | 4.8% | +22.5% |
| Luye Pharma 2186.HK | Hong Kong | $839M | -36% | +3% | 18% | 8.1× | -10.5% | +1.9% |
| Latigo Biotherapeutics LTGO | United States | $835M | n/a | n/a | n/a | n/a | n/a | n/a |
| Pharming PHARM.AS | Netherlands | $874M | -2% | +2% | 9% | 41.4× | 2.5% | +12.4% |
| Daewoong Pharm 069620.KS | South Korea | $874M | -30% | +9% | 12% | 5.8× | n/a | n/a |
| Sanofi Consumer Healthcare India SANOFICONR.NS | India | $835M | -28% | +23% | 36% | 27.2× | 17.1% | +22.7% |
| Aktis Oncology AKTS | United States | $880M | -15% | +337% | -1,150% | n/a | n/a | n/a |
| Zhejiang Int'l 000411.SZ | China | $828M | -8% | +3% | 3% | n/a | n/a | n/a |
| CARsgen Therapeutics 2171.HK | Hong Kong | $825M | -54% | +68% | -170% | n/a | n/a | n/a |
| Jinghua Pharmaceutical 002349.SZ | China | $825M | -8% | +2% | 20% | n/a | -1.8% | +2.6% |
| Corvus Pharmaceuticals CRVS | United States | $887M | -32% | n/a | n/a | n/a | n/a | n/a |
| Aarti Pharmalabs AARTIPHARM.NS | India | $892M | +19% | +13% | 18% | n/a | n/a | n/a |
| Zhejiang Ausun Pharmaceutical 603229.SS | China | $893M | -27% | +1% | 0% | n/a | n/a | n/a |
| Beijing Sun-Novo Pharmaceutical Research 688621.SS | China | $894M | -8% | -1% | -2% | 30.6× | n/a | n/a |
| Chongqing Pharscin Pharmaceutical 002907.SZ | China | $808M | -7% | +8% | 10% | n/a | 10.7% | -1.4% |
| Guizhou Xinbang Pharmaceutical 002390.SZ | China | $805M | -10% | -13% | 4% | n/a | -3.0% | -0.8% |
| Alumis ALMS | United States | $805M | -27% | -63% | -5,480% | n/a | n/a | n/a |
| Guizhou Bailing Group Pharmaceutical 002424.SZ | China | $907M | -12% | -25% | 2% | n/a | 16.2% | -0.2% |
| SK Discovery 006120.KS | South Korea | $804M | +11% | +20% | 3% | n/a | n/a | n/a |
| Wanbangde Pharmaceutical 002082.SZ | China | $909M | -65% | -11% | -3% | n/a | -1.2% | -39.5% |